Our Services
Medical Information
Helpful Resources
Published on: 2/24/2026
Common Mounjaro side effects are mostly digestive, including nausea, vomiting, diarrhea, constipation, bloating, and stomach pain from slowed stomach emptying; they are often worst at start or after dose increases and can improve with smaller low fat meals, slow eating, staying upright, hydration, and doctor guided dose adjustments or anti nausea medication.
Seek urgent care for severe or persistent abdominal pain, ongoing vomiting, signs of pancreatitis or gallbladder problems, dehydration, allergic symptoms, or low blood sugar if also using insulin or sulfonylureas, and avoid use with certain thyroid conditions. There are several factors to consider, and the complete red flags and step by step next actions are detailed below.
Mounjaro (tirzepatide) is a prescription medication used to treat type 2 diabetes and is also widely prescribed for chronic weight management. It works by targeting two hormone receptors in the body (GLP‑1 and GIP), which help regulate blood sugar, appetite, and digestion.
While Mounjaro can be highly effective, many people experience side effects — especially when starting treatment or increasing their dose. If you're feeling sick while taking Mounjaro, you're not alone. Understanding why it happens and knowing what to do next can make a big difference.
Mounjaro works by slowing down how quickly food leaves your stomach. This helps you feel full longer and reduces appetite. However, this slowed digestion is also the main reason many people feel unwell.
When food sits in the stomach longer than usual, it can cause:
These effects are usually strongest when:
For many people, symptoms improve within a few weeks as the body adjusts.
The most frequently reported side effects in clinical trials include:
These are typically mild to moderate and temporary.
Most of these are manageable with simple adjustments.
Nausea is the number one complaint with Mounjaro. This happens because:
If your stomach empties more slowly than usual, food may linger, leading to queasiness.
If nausea is severe or persistent, your doctor may:
Mild stomach discomfort is common. However, severe or persistent abdominal pain is not something to ignore.
Mounjaro carries warnings about rare but serious conditions such as:
Symptoms may include:
This requires immediate medical evaluation.
Rapid weight loss can increase the risk of gallstones. Watch for:
If food barely moves through the stomach, symptoms may include:
If you are unsure whether your symptoms are typical or concerning, try this free AI-powered Abdominal Discomfort symptom checker to help identify what may be causing your pain and whether you should seek immediate care.
However, this should not replace medical care.
Mounjaro alone has a low risk of causing dangerously low blood sugar. However, if you also take:
Your risk increases.
Symptoms of low blood sugar include:
If severe, hypoglycemia can be life‑threatening. Always speak to your doctor about adjusting other diabetes medications when starting Mounjaro.
Mounjaro carries a boxed warning about thyroid C‑cell tumors seen in animal studies. While it is unclear whether this risk applies to humans, you should not use Mounjaro if you:
Call your doctor if you notice:
Because Mounjaro can cause vomiting or diarrhea, dehydration is possible — especially early on.
Watch for:
Drink fluids regularly, even if you don't feel thirsty.
Do not wait or "push through" symptoms if you experience:
These could be life‑threatening and require urgent care. Speak to a doctor immediately.
For most people:
If symptoms do not improve after several weeks, your provider may:
Here is a calm, practical approach:
Track your symptoms.
Adjust your eating habits.
Stay hydrated.
Review your dose schedule.
Speak to your doctor.
Do not stop Mounjaro suddenly without medical guidance unless you are experiencing a serious reaction.
Mounjaro is an effective medication for blood sugar control and weight management. However, digestive side effects are common — especially nausea, vomiting, and abdominal discomfort.
Most symptoms are temporary and manageable. That said, severe abdominal pain, persistent vomiting, or signs of pancreatitis or gallbladder disease require prompt medical evaluation.
You know your body best. Mild nausea may be expected. Severe, ongoing pain is not.
If you are unsure whether what you're experiencing is normal, use a symptom checker for Abdominal Discomfort to get personalized insights and then review the results with a healthcare provider.
Above all, speak to a doctor about any symptoms that feel serious, unusual, or potentially life‑threatening. Mounjaro can be a powerful tool for better health — but safe use always comes first.
(References)
* Jastreboff AM, Aronne LJ, Ahmad NN, Wharton L, Collazo-Clavell ER, Portocarrero C, Van Gaal KJ, Bunck MC, Forhan SE, Garcia DG, Neff LM. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.
* Frías JP, Davies MJ, Rosenstock J, Saxon B, Baumgartner K, Rodríguez-Cano AM, Adkins N, Kuo J, Maldonado M. Tirzepatide versus insulin glargine in type 2 diabetes and high cardiovascular risk: results from the SURPASS-4 trial. Lancet. 2021 Oct 23;398(10300):583-595. doi: 10.1016/S0140-6736(21)01442-7. Epub 2021 Jul 2. PMID: 34224747.
* Wilding JPH, Batterham RL, Blickensderfer A, Davies MJ, Geloneze B, Lam D, Lau D, Ludvik B, Lingvay I, Mosenzon O, Rosenstock J, Rüttimann H, Thoma C, Trujillo S, Wintle M, Yang M, Nauck MA. Tirzepatide (Mounjaro®) for the treatment of type 2 diabetes and obesity: a review of the clinical trial data. Diabetes Obes Metab. 2023 Apr;25 Suppl 1:3-22. doi: 10.1111/dom.14930. PMID: 36720743; PMCID: PMC10092147.
* Chavda VP, Vihol PB, Mehta M, Balar P. Tirzepatide, a dual GIP and GLP-1 receptor agonist, for the treatment of type 2 diabetes with associated comorbidities: a review. J Diabetes Metab Disord. 2022 Mar 2;21(1):505-515. doi: 10.1007/s40200-022-00991-6. PMID: 35242439; PMCID: PMC8890250.
* Ludvik B, Gillard P, Zhang S, Kothny W, Ahmad NN, Erondu N. Safety, Tolerability, and Weight Outcomes of Tirzepatide in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Obes Metab. 2022 Jul;24(7):1260-1271. doi: 10.1111/dom.14660. Epub 2022 Mar 22. PMID: 35243640; PMCID: PMC9287870.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.